Advances in genome-wide association studies of sporadic Alzheimer’s disease / 国际药学研究杂志

Alzheimer’s disease AD is a neurodegenerative disorder resulted from complicate interactions between genes and environment. There is no effective therapy so far. The genome-wide association study GWAS provides the opportunity to discover the risk genes of sporadic AD, which is informative for revealing the pathogenesis of AD and guiding new drug development. In this review, we summarize the current findings of genetic studies of AD, the risk genes and their biological relevance with AD, and new drug development strategy supported by genetic studies.

Advances in genome-wide association studies of sporadic Alzheimer′s disease / 国际药学研究杂志

Alzheimer′s disease(AD)is a neurodegenerative disorder resulted from complicate interactions between genes and environment. There is no effective therapy so far. The genome-wide association study(GWAS)provides the opportunity to discover the risk genes of sporadic AD,which is informative for revealing the pathogenesis of AD and guiding new drug development. In this re?view,we summarize the current findings of genetic studies of AD,the risk genes and their biological relevance with AD,and new drug development strategy supported by genetic studies.